search
Back to results

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

Primary Purpose

Gastro-enteropancreatic Neuroendocrine Tumor

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
CAM2029
Octreotide LAR
Lanreotide ATG
Sponsored by
Camurus AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastro-enteropancreatic Neuroendocrine Tumor focused on measuring CAM2029, GEP-NET, Octreotide, SORENTO

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patient ≥18 years old
  • Histologically confirmed, advanced (unresectable and/or metastatic), and well-differentiated NET of GEP or presumed GEP origin
  • At least 1 measurable, somatostatin receptor-positive lesion according to RECIST 1.1 determined by multiphasic CT or MRI (performed within 28 days before randomization)
  • ECOG performance status of 0 to 2

Exclusion Criteria:

  • Documented evidence of disease progression while on treatment (including SSAs) for locally advanced unresectable or metastatic disease
  • Known central nervous system metastases
  • Consecutive treatment with long-acting SSAs for more than 6 months before randomization
  • Carcinoid symptoms that are refractory to treatment (according to the Investigator's judgement) with conventional doses of octreotide LAR or lanreotide ATG and/or to treatment with daily doses of ≤600 µg of octreotide IR
  • Previous treatment with more than 1 cycle of targeted therapies such as mTOR inhibitors or vascular endothelial growth factor inhibitors, or more than 1 cycle of chemotherapy or interferon for GEP-NET
  • Treatment of GEP-NET with trans-arterial chemoembolization or trans-arterial embolization within 12 months before screening
  • Previously received radioligand therapy (PRRT) at any time

Sites / Locations

  • Mayo Clinic Cancer Center (MCCC) - PhoenixRecruiting
  • UCLA Ahmanson Biological Imaging CenterRecruiting
  • Rocky Mountain Cancer Centers - Denver - MidtownRecruiting
  • Mayo Clinic Hospital - FloridaRecruiting
  • Anderson Family Cancer InstituteRecruiting
  • University of Kentucky (UK) - Markey Cancer CenterRecruiting
  • East Jefferson General HospitalRecruiting
  • Dana-Farber Cancer InstituteRecruiting
  • Mayo Clinic RochesterRecruiting
  • The Mount Sinai HospitalRecruiting
  • Memorial Sloan-Kettering Cancer CenterRecruiting
  • White Plains Hospital - Center for Cancer CareRecruiting
  • Texas Oncology - AustinRecruiting
  • Texas Oncology - DallasRecruiting
  • Texas Oncology - Denton NorthRecruiting
  • The University of Texas - MD Anderson Cancer CenterRecruiting
  • Texas Oncology - McAllenRecruiting
  • Texas Oncology - San Antonio NortheastRecruiting
  • Huntsman Cancer InstituteRecruiting
  • The Queen Elizabeth Hospital (TQEH)Recruiting
  • GenesisCare - North ShoreRecruiting
  • Peter MacCallum Cancer CentreRecruiting
  • Fiona Stanley HospitalRecruiting
  • Cliniques Universitaires Saint-LucRecruiting
  • Hôpital ErasmeRecruiting
  • Antwerp University HospitalRecruiting
  • Algemeen Ziekenhuis Maria MiddelaresRecruiting
  • Universitair Ziekenhuis LeuvenRecruiting
  • Centre Hospitalier Chretien (CHC) - Clinique Notre-Dame - HermalleRecruiting
  • AZ NikolaasRecruiting
  • London Health Sciences CentreRecruiting
  • Centre Hospitalier de l'Universite de Montreal - Notre-Dame HospitalRecruiting
  • Jewish General HospitalRecruiting
  • The Ottawa Hospital - General CampusRecruiting
  • Niagara Health System - St. Catharines General SiteRecruiting
  • Princess Margaret Cancer CentreRecruiting
  • Sunnybrook Health Sciences CentreRecruiting
  • BC Cancer Agency Vancouver CentreRecruiting
  • CHU Hopitaux de Bordeaux - Hôpital Haut-LévêqueRecruiting
  • CHRU Brest - Hopital Morvan - Institut de Cancerologie et d'HematologieRecruiting
  • CHRU de Tours - Hopital TrousseauRecruiting
  • Centre Hospitalier Universitaire Dijon Bourgogne - L'Hopital GeneralRecruiting
  • Groupe Hospitalier de l'Institut Catholique de Lille - Hopital Saint Vincent de PaulRecruiting
  • CHU de Lyon - Groupement Hospitalier Edouard HerriotRecruiting
  • CHU de Nantes - Hôtel-DieuRecruiting
  • CHU de PoitiersRecruiting
  • Centre Eugène MarquisRecruiting
  • Hôpitaux Universitaires de Strasbourg - Hôpital de HautepierreRecruiting
  • Charite - UB - CVK - Medizinische KlinikRecruiting
  • Universitätsklinikum EssenRecruiting
  • Asklepios Klinik St. GeorgRecruiting
  • Universitätsklinikum Hamburg-Eppendorf (UKE)Recruiting
  • Nationales Centrum für Tumorerkrankungen (NCT) HeidelbergRecruiting
  • Medizinischen Fakultät Mannheim der Universität HeidelbergRecruiting
  • Universitätsklinikum UlmRecruiting
  • SE ÁOK I. sz. Belgyógyászati KlinikaRecruiting
  • Petz Aladár Megyei Oktató KórházRecruiting
  • Bács-Kiskun Megyei KórházRecruiting
  • Szegedi Tudományegyetem; I.Belgyógyászati KlinikaRecruiting
  • Rambam Medical CenterRecruiting
  • Hadassah Medical Center (HMC) - Hadassah University Hospital (HUH) - Ein KeremRecruiting
  • The Chaim Sheba Medical CenterRecruiting
  • Tel Aviv Sourasky Medical CenterRecruiting
  • Centro di Riferimento Oncologico (CRO)Recruiting
  • Universita degli Studi di Bari - Aldo MoroRecruiting
  • Azienda Ospedaliero - Universitaria di Bologna Policlinico S. Orsola - MalpighiRecruiting
  • ASST degli Spedali Civili di BresciaRecruiting
  • Universita degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - SC di Oncologia MedicalRecruiting
  • Universita Degli Studi di Genova - Center of Excellence for Biomedical Research (CEBR)Recruiting
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCSRecruiting
  • Istituto Clinico HumanitasRecruiting
  • Azienda Ospedaliero - Universitaria di Modena PoliclinicoRecruiting
  • IRCCS - Istituto Nazionale dei Tumori di Napoli Fondazione G. Pascale - Oncologia AddominaleRecruiting
  • Istituto Oncologico Veneto - IRCCSRecruiting
  • Azienda Ospedaliera Sant'AndreaRecruiting
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo TrentoRecruiting
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek ZiekenhuisRecruiting
  • Rijnstate Ziekenhuis - ArnhemRecruiting
  • Maastricht UMC+Recruiting
  • Erasmus MCRecruiting
  • Institutul Clinic FundeniRecruiting
  • Institutul Oncologic "Prof. Dr. Ion Chiricuţă" Cluj NapocaRecruiting
  • Medisprof SRLRecruiting
  • Centrul de Oncologie Sfantul NectarieRecruiting
  • Onco Clinic Consult SARecruiting
  • Sigmedical Services S.R.L.Recruiting
  • Complexo Hospitalario Universitario A CoruñaRecruiting
  • Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO)Recruiting
  • Institut Catala d'Oncologia HospitaletRecruiting
  • Hospital General Universitario de ElcheRecruiting
  • Hospital Universitari de Girona Doctor Josep TruetaRecruiting
  • Facultad de Medicina - Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) (Clinica de la Concepcion)Recruiting
  • Hospital Universitario Fundación AlcorcónRecruiting
  • Hospital Universitario La Paz (HULP)Recruiting
  • Hospital Universitario Ramón y CajalRecruiting
  • MD Anderson Cancer Center - MadridRecruiting
  • Hospital General Universitario Morales MeseguerRecruiting
  • Hospital Universitario Virgen de la VictoriaRecruiting
  • Hospital Universitario Central de AsturiasRecruiting
  • Parc Taulí Sabadell Hospital UniversitariRecruiting
  • Hospital Universitario Marques de Valdecilla (HUMV)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

CAM2029

Octreotide LAR or lanreotide ATG

Arm Description

Outcomes

Primary Outcome Measures

Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)
PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)

Secondary Outcome Measures

Overall survival
The time from the date of randomization to the date of death due to any cause
PFS as assessed by local Investigators
PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)
Overall response rate
The proportion of patients with best overall response of complete response (CR) or partial response (PR), as per BIRC according to RECIST 1.1
Disease control rate
The proportion of patients with a best overall response of CR, PR or stable disease (SD), as per BIRC according to RECIST 1.1
Time to tumor response
The time from the date of randomization to the first documented response of CR or PR, as per BIRC according to RECIST 1.1
Duration of response
The time from the date of the first documented response of CR or PR to the date of the first documented progression or death due to underlying cancer, as per BIRC according to RECIST 1.1
Incidence of treatment-emergent adverse events

Full Information

First Posted
September 9, 2021
Last Updated
October 5, 2023
Sponsor
Camurus AB
search

1. Study Identification

Unique Protocol Identification Number
NCT05050942
Brief Title
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Acronym
SORENTO
Official Title
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 22, 2021 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Camurus AB

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastro-enteropancreatic Neuroendocrine Tumor
Keywords
CAM2029, GEP-NET, Octreotide, SORENTO

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CAM2029
Arm Type
Experimental
Arm Title
Octreotide LAR or lanreotide ATG
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
CAM2029
Intervention Description
CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
Octreotide LAR
Intervention Description
Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
Intervention Type
Drug
Intervention Name(s)
Lanreotide ATG
Intervention Description
Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
Primary Outcome Measure Information:
Title
Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)
Description
PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)
Time Frame
From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months
Secondary Outcome Measure Information:
Title
Overall survival
Description
The time from the date of randomization to the date of death due to any cause
Time Frame
Up to 2 years following the primary efficacy analysis
Title
PFS as assessed by local Investigators
Description
PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)
Time Frame
From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months
Title
Overall response rate
Description
The proportion of patients with best overall response of complete response (CR) or partial response (PR), as per BIRC according to RECIST 1.1
Time Frame
From date of randomization until disease progression, assessed up to 48 months
Title
Disease control rate
Description
The proportion of patients with a best overall response of CR, PR or stable disease (SD), as per BIRC according to RECIST 1.1
Time Frame
From date of randomization until disease progression, assessed up to 48 months
Title
Time to tumor response
Description
The time from the date of randomization to the first documented response of CR or PR, as per BIRC according to RECIST 1.1
Time Frame
From date of randomization until disease progression, assessed up to 48 months
Title
Duration of response
Description
The time from the date of the first documented response of CR or PR to the date of the first documented progression or death due to underlying cancer, as per BIRC according to RECIST 1.1
Time Frame
From date of randomization until disease progression or death due to underlying cancer, whichever comes first, assessed up to 48 months
Title
Incidence of treatment-emergent adverse events
Time Frame
From screening to the safety follow-up, assessed up to 6 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patient ≥18 years old Histologically confirmed, advanced (unresectable and/or metastatic), and well-differentiated NET of GEP or presumed GEP origin At least 1 measurable, somatostatin receptor-positive lesion according to RECIST 1.1 determined by multiphasic CT or MRI (performed within 28 days before randomization) ECOG performance status of 0 to 2 Exclusion Criteria: Documented evidence of disease progression while on treatment (including SSAs) for locally advanced unresectable or metastatic disease Known central nervous system metastases Consecutive treatment with long-acting SSAs for more than 6 months before randomization Carcinoid symptoms that are refractory to treatment (according to the Investigator's judgement) with conventional doses of octreotide LAR or lanreotide ATG and/or to treatment with daily doses of ≤600 µg of octreotide IR Previous treatment with more than 1 cycle of targeted therapies such as mTOR inhibitors or vascular endothelial growth factor inhibitors, or more than 1 cycle of chemotherapy or interferon for GEP-NET Treatment of GEP-NET with trans-arterial chemoembolization or trans-arterial embolization within 12 months before screening Previously received radioligand therapy (PRRT) at any time
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Camurus AB
Phone
+46 46 286 57 30
Email
medicalinfo@camurus.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simron Singh, MD, MPH
Organizational Affiliation
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic Cancer Center (MCCC) - Phoenix
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Individual Site Status
Recruiting
Facility Name
UCLA Ahmanson Biological Imaging Center
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Individual Site Status
Recruiting
Facility Name
Rocky Mountain Cancer Centers - Denver - Midtown
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Individual Site Status
Recruiting
Facility Name
Mayo Clinic Hospital - Florida
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Individual Site Status
Recruiting
Facility Name
Anderson Family Cancer Institute
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Kentucky (UK) - Markey Cancer Center
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Individual Site Status
Recruiting
Facility Name
East Jefferson General Hospital
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70065
Country
United States
Individual Site Status
Recruiting
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Name
Mayo Clinic Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Name
The Mount Sinai Hospital
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Individual Site Status
Recruiting
Facility Name
Memorial Sloan-Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Name
White Plains Hospital - Center for Cancer Care
City
White Plains
State/Province
New York
ZIP/Postal Code
10601
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology - Austin
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology - Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology - Denton North
City
Denton
State/Province
Texas
ZIP/Postal Code
76201
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Texas - MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology - McAllen
City
McAllen
State/Province
Texas
ZIP/Postal Code
78503
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology - San Antonio Northeast
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78240
Country
United States
Individual Site Status
Recruiting
Facility Name
Huntsman Cancer Institute
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Individual Site Status
Recruiting
Facility Name
The Queen Elizabeth Hospital (TQEH)
City
Adelaide
Country
Australia
Individual Site Status
Recruiting
Facility Name
GenesisCare - North Shore
City
Alexandria
Country
Australia
Individual Site Status
Recruiting
Facility Name
Peter MacCallum Cancer Centre
City
Melbourne
Country
Australia
Individual Site Status
Recruiting
Facility Name
Fiona Stanley Hospital
City
Murdoch
Country
Australia
Individual Site Status
Recruiting
Facility Name
Cliniques Universitaires Saint-Luc
City
Brussels
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Hôpital Erasme
City
Brussels
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Antwerp University Hospital
City
Edegem
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Algemeen Ziekenhuis Maria Middelares
City
Gent
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Universitair Ziekenhuis Leuven
City
Leuven
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Centre Hospitalier Chretien (CHC) - Clinique Notre-Dame - Hermalle
City
Liège
Country
Belgium
Individual Site Status
Recruiting
Facility Name
AZ Nikolaas
City
Sint-Niklaas
Country
Belgium
Individual Site Status
Recruiting
Facility Name
London Health Sciences Centre
City
London
Country
Canada
Individual Site Status
Recruiting
Facility Name
Centre Hospitalier de l'Universite de Montreal - Notre-Dame Hospital
City
Montréal
Country
Canada
Individual Site Status
Recruiting
Facility Name
Jewish General Hospital
City
Montréal
Country
Canada
Individual Site Status
Recruiting
Facility Name
The Ottawa Hospital - General Campus
City
Ottawa
Country
Canada
Individual Site Status
Recruiting
Facility Name
Niagara Health System - St. Catharines General Site
City
St. Catharines
Country
Canada
Individual Site Status
Recruiting
Facility Name
Princess Margaret Cancer Centre
City
Toronto
Country
Canada
Individual Site Status
Recruiting
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
Country
Canada
Individual Site Status
Recruiting
Facility Name
BC Cancer Agency Vancouver Centre
City
Vancouver
Country
Canada
Individual Site Status
Recruiting
Facility Name
CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
City
Bordeaux
Country
France
Individual Site Status
Recruiting
Facility Name
CHRU Brest - Hopital Morvan - Institut de Cancerologie et d'Hematologie
City
Brest
Country
France
Individual Site Status
Recruiting
Facility Name
CHRU de Tours - Hopital Trousseau
City
Chambray-lès-Tours
Country
France
Individual Site Status
Recruiting
Facility Name
Centre Hospitalier Universitaire Dijon Bourgogne - L'Hopital General
City
Dijon
Country
France
Individual Site Status
Recruiting
Facility Name
Groupe Hospitalier de l'Institut Catholique de Lille - Hopital Saint Vincent de Paul
City
Lille
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Lyon - Groupement Hospitalier Edouard Herriot
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Nantes - Hôtel-Dieu
City
Nantes
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Poitiers
City
Poitiers
Country
France
Individual Site Status
Recruiting
Facility Name
Centre Eugène Marquis
City
Rennes
Country
France
Individual Site Status
Recruiting
Facility Name
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
City
Strasbourg
Country
France
Individual Site Status
Recruiting
Facility Name
Charite - UB - CVK - Medizinische Klinik
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Essen
City
Essen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Asklepios Klinik St. Georg
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Hamburg-Eppendorf (UKE)
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
City
Heidelberg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Medizinischen Fakultät Mannheim der Universität Heidelberg
City
Mannheim
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Ulm
City
Ulm
Country
Germany
Individual Site Status
Recruiting
Facility Name
SE ÁOK I. sz. Belgyógyászati Klinika
City
Budapest
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Petz Aladár Megyei Oktató Kórház
City
Győr
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Bács-Kiskun Megyei Kórház
City
Kecskemét
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Szegedi Tudományegyetem; I.Belgyógyászati Klinika
City
Szeged
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Rambam Medical Center
City
Haifa
Country
Israel
Individual Site Status
Recruiting
Facility Name
Hadassah Medical Center (HMC) - Hadassah University Hospital (HUH) - Ein Kerem
City
Jerusalem
Country
Israel
Individual Site Status
Recruiting
Facility Name
The Chaim Sheba Medical Center
City
Ramat Gan
Country
Israel
Individual Site Status
Recruiting
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
Country
Israel
Individual Site Status
Recruiting
Facility Name
Centro di Riferimento Oncologico (CRO)
City
Aviano
Country
Italy
Individual Site Status
Recruiting
Facility Name
Universita degli Studi di Bari - Aldo Moro
City
Bari
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero - Universitaria di Bologna Policlinico S. Orsola - Malpighi
City
Bologna
Country
Italy
Individual Site Status
Recruiting
Facility Name
ASST degli Spedali Civili di Brescia
City
Brescia
Country
Italy
Individual Site Status
Recruiting
Facility Name
Universita degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - SC di Oncologia Medical
City
Firenze
Country
Italy
Individual Site Status
Recruiting
Facility Name
Universita Degli Studi di Genova - Center of Excellence for Biomedical Research (CEBR)
City
Genova
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS
City
Meldola
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto Clinico Humanitas
City
Milan
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero - Universitaria di Modena Policlinico
City
Modena
Country
Italy
Individual Site Status
Recruiting
Facility Name
IRCCS - Istituto Nazionale dei Tumori di Napoli Fondazione G. Pascale - Oncologia Addominale
City
Napoli
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto Oncologico Veneto - IRCCS
City
Padova
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliera Sant'Andrea
City
Roma
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
City
Verona
Country
Italy
Individual Site Status
Recruiting
Facility Name
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
City
Amsterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Rijnstate Ziekenhuis - Arnhem
City
Arnhem
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Maastricht UMC+
City
Maastricht
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Erasmus MC
City
Rotterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Institutul Clinic Fundeni
City
Bucharest
Country
Romania
Individual Site Status
Recruiting
Facility Name
Institutul Oncologic "Prof. Dr. Ion Chiricuţă" Cluj Napoca
City
Cluj-Napoca
Country
Romania
Individual Site Status
Recruiting
Facility Name
Medisprof SRL
City
Cluj-Napoca
Country
Romania
Individual Site Status
Recruiting
Facility Name
Centrul de Oncologie Sfantul Nectarie
City
Craiova
Country
Romania
Individual Site Status
Recruiting
Facility Name
Onco Clinic Consult SA
City
Craiova
Country
Romania
Individual Site Status
Recruiting
Facility Name
Sigmedical Services S.R.L.
City
Suceava
Country
Romania
Individual Site Status
Recruiting
Facility Name
Complexo Hospitalario Universitario A Coruña
City
A Coruña
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO)
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Institut Catala d'Oncologia Hospitalet
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario de Elche
City
Elche
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari de Girona Doctor Josep Trueta
City
Girona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Facultad de Medicina - Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) (Clinica de la Concepcion)
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Fundación Alcorcón
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario La Paz (HULP)
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Ramón y Cajal
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
MD Anderson Cancer Center - Madrid
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario Morales Meseguer
City
Murcia
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen de la Victoria
City
Málaga
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Central de Asturias
City
Oviedo
Country
Spain
Individual Site Status
Recruiting
Facility Name
Parc Taulí Sabadell Hospital Universitari
City
Sabadell
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Marques de Valdecilla (HUMV)
City
Santander
Country
Spain
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

We'll reach out to this number within 24 hrs